WO2000014097A3 - Neue pyranosen - Google Patents

Neue pyranosen Download PDF

Info

Publication number
WO2000014097A3
WO2000014097A3 PCT/EP1999/006325 EP9906325W WO0014097A3 WO 2000014097 A3 WO2000014097 A3 WO 2000014097A3 EP 9906325 W EP9906325 W EP 9906325W WO 0014097 A3 WO0014097 A3 WO 0014097A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
pyranoses
compounds
formula
description
Prior art date
Application number
PCT/EP1999/006325
Other languages
English (en)
French (fr)
Other versions
WO2000014097A2 (de
Inventor
Josef Stadlwieser
Wolf-Ruediger Ulrich
Andreas Dominik
Daniela Bundschuh
Manfrid Eltze
Karl Zech
Christian Sommerhoff
Thomas Martin
Thomas Baer
Original Assignee
Byk Gulden Lomberg Chem Fab
Thomas Martin
Thomas Baer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab, Thomas Martin, Thomas Baer filed Critical Byk Gulden Lomberg Chem Fab
Priority to EP99942928A priority Critical patent/EP1115731A2/de
Priority to CA002342855A priority patent/CA2342855A1/en
Priority to AU56254/99A priority patent/AU5625499A/en
Priority to JP2000568855A priority patent/JP2003524598A/ja
Priority to IL14165499A priority patent/IL141654A0/xx
Publication of WO2000014097A2 publication Critical patent/WO2000014097A2/de
Publication of WO2000014097A3 publication Critical patent/WO2000014097A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Verbindungen der Formel (I), worin M, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, B5, B6, K1 und K2 die in der Beschreibung angegebenen Bedeutungen haben, sind neue wirksame Tryptase-Inhibitoren.
PCT/EP1999/006325 1998-09-04 1999-08-27 Neue pyranosen WO2000014097A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99942928A EP1115731A2 (de) 1998-09-04 1999-08-27 Neue pyranosen
CA002342855A CA2342855A1 (en) 1998-09-04 1999-08-27 Novel pyranoses
AU56254/99A AU5625499A (en) 1998-09-04 1999-08-27 Novel pyranoses
JP2000568855A JP2003524598A (ja) 1998-09-04 1999-08-27 新規ピラノセン
IL14165499A IL141654A0 (en) 1998-09-04 1999-08-27 Pyranose derivatives and pharmaceutical compositions containing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98116777 1998-09-04
EP98116777.8 1998-09-04
DE19937718.9 1999-08-10
DE19937718 1999-08-10

Publications (2)

Publication Number Publication Date
WO2000014097A2 WO2000014097A2 (de) 2000-03-16
WO2000014097A3 true WO2000014097A3 (de) 2000-07-20

Family

ID=26054555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006325 WO2000014097A2 (de) 1998-09-04 1999-08-27 Neue pyranosen

Country Status (6)

Country Link
EP (1) EP1115731A2 (de)
JP (1) JP2003524598A (de)
AU (1) AU5625499A (de)
CA (1) CA2342855A1 (de)
IL (1) IL141654A0 (de)
WO (1) WO2000014097A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036386A1 (fr) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Traitement du diabete contenant un derive de dipiperazine
CA2392121A1 (en) 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
US6815557B2 (en) 1999-12-20 2004-11-09 Altana Pharma Ag Tryptase inhibitors
ATE273302T1 (de) 2001-01-31 2004-08-15 Altana Pharma Ag Diazocinderivate und deren verwendung als tryptase inhibitoren
WO2002066420A2 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
WO2002066430A1 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
CA2450659A1 (en) 2001-06-19 2002-12-27 Altana Pharma Ag Tryptase inhibitors
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP2431744A1 (de) * 2010-09-20 2012-03-21 Bioftalmik, S.L. Diagnostisches in vitro Verfahren zum Nachweis von Allergien des Auges bei Kindern
US20210087143A1 (en) * 2017-03-29 2021-03-25 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017032A1 (en) * 1992-02-24 1993-09-02 The Trustees Of The University Of Pennsylvania Techniques and intermediates for preparing non-peptide peptidomimetics
WO1993020078A1 (en) * 1992-04-03 1993-10-14 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
EP0652225A1 (de) * 1993-11-08 1995-05-10 ASTA Medica Aktiengesellschaft Verwendung von D-glucopyranuronsäuren und deren Derivate zum Einbau in pharmakologisch wirksame Peptide und deren Salze
WO1995029681A1 (en) * 1994-04-29 1995-11-09 Texas Biotechnology Corporation COMPOSITIONS AND METHODS FOR INHIBITING THE BINDING OF E-SELECTIN OR P-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
WO1997001335A1 (en) * 1995-06-29 1997-01-16 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
WO1998004537A1 (en) * 1996-07-30 1998-02-05 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity
DE19637123A1 (de) * 1996-09-12 1998-03-19 Boehringer Ingelheim Kg Neue Pyranosidderivate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017032A1 (en) * 1992-02-24 1993-09-02 The Trustees Of The University Of Pennsylvania Techniques and intermediates for preparing non-peptide peptidomimetics
WO1993020078A1 (en) * 1992-04-03 1993-10-14 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
EP0652225A1 (de) * 1993-11-08 1995-05-10 ASTA Medica Aktiengesellschaft Verwendung von D-glucopyranuronsäuren und deren Derivate zum Einbau in pharmakologisch wirksame Peptide und deren Salze
WO1995029681A1 (en) * 1994-04-29 1995-11-09 Texas Biotechnology Corporation COMPOSITIONS AND METHODS FOR INHIBITING THE BINDING OF E-SELECTIN OR P-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
WO1997001335A1 (en) * 1995-06-29 1997-01-16 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
WO1998004537A1 (en) * 1996-07-30 1998-02-05 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity
DE19637123A1 (de) * 1996-09-12 1998-03-19 Boehringer Ingelheim Kg Neue Pyranosidderivate

Also Published As

Publication number Publication date
JP2003524598A (ja) 2003-08-19
IL141654A0 (en) 2002-03-10
AU5625499A (en) 2000-03-27
CA2342855A1 (en) 2000-03-16
WO2000014097A2 (de) 2000-03-16
EP1115731A2 (de) 2001-07-18

Similar Documents

Publication Publication Date Title
AU4659900A (en) Treating compositions comprising polysaccharides
WO1999040083A3 (de) Bifunktionelle tryptase-inhibitoren
AU4838100A (en) Online virtual campus
AU6780400A (en) Wear resistant topical compositions having improved feel
AU1777601A (en) Electronic book having electronic commerce features
EP1145479A3 (de) Bidirektionale, anonyme, elektronische transactionen
AU4541800A (en) Organosiloxane compositions
WO2001027118A3 (de) Bicyclische imidazo-5-yl-aminderivate
AU2001282780A1 (en) Two stage data packet processing scheme
AU2003218121A1 (en) Lotion compositions
AU4290899A (en) Composite ic card
WO2000014097A3 (de) Neue pyranosen
AU4548000A (en) Laundry compositions
AU4431599A (en) Organosilicone compositions for personal care
AU2196401A (en) Improvements in or relating to internet access
AU1684400A (en) Substituted benzylamines
AU4290799A (en) Composite ic card
AUPQ197899A0 (en) Biomedical compositions
AU5902900A (en) Detergent compositions or components
AU5085300A (en) Compositions
WO2001046128A3 (en) Tryptase inhibitors
IL147649A0 (en) Tryptase inhibitors
AU2349901A (en) Virtual bank
AU7796300A (en) Tenocyte compositions and production and uses thereof
AU2996200A (en) Fabric enhancement compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 56254/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999942928

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09744975

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001/01562

Country of ref document: ZA

Ref document number: 141654

Country of ref document: IL

Ref document number: 200101562

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2342855

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 568855

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2342855

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999942928

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999942928

Country of ref document: EP